Presentation is loading. Please wait.

Presentation is loading. Please wait.

Patients were considered not in MDA (MDA<sup>−</sup>) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA<sup>+</sup>) with a score of 5, 6 or 7 points.

Published byMarvin Sherman Modified over 6 years ago

Similar presentations

Presentation on theme: "Patients were considered not in MDA (MDA<sup>−</sup>) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA<sup>+</sup>) with a score of 5, 6 or 7 points."— Presentation transcript:

1 Patients were considered not in MDA (MDA<sup>−</sup>) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA<sup>+</sup>) with a score of 5, 6 or 7 points. MDA: minimal disease activity. From: Residual disease activity in psoriatic arthritis: discordance between the rheumatologist’s opinion and minimal disease activity measurement Rheumatology (Oxford). Published online May 24, doi: /rheumatology/kex183 Rheumatology (Oxford) | © The Author Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please

2 (A) The percentage of patients failing specific MDA criterion in the MDA subgroups. (B) Percentage of MDA patients failing specific MDA criterion according to gender. (C and D) PRO scores in MDA subgroups. Significance of the comparisons is determined by an independent sample t-test for continues variables and Mann–Whitney U test when non-normally distributed. P < 0.05 was considered significant and indicated with an asterisks. Cutoff points for values were used according to the MDA scoring: VASptGlobal > 20 mm; VASptPain > 15 mm; SJC > 1; TJC > 1; PASI > 1; LEI > 1; HAQ > 0.5. DLQI: Dermatology Quality of Life Index; HADS: Hospital Anxiety and Depression Scale; LEI: Leeds Enthesitis Index; MDA: minimal disease activity; PASI: Psoriasis Area Severity Index; PRO: patient reported outcome; SF-36 MCS: Short Form 36, mental impact of disease; SF-36 PCS: Short Form 36, physical disability; SJC: swollen joint count; TJC: tender joint count; VASptGlobal: the patient global assessment of disease activity on a VAS; VASptPain: the patient assessment of pain on a VAS; WPAI ADL: Work Productivity Assessment Index, patient perception on impairment in daily life activities. From: Residual disease activity in psoriatic arthritis: discordance between the rheumatologist’s opinion and minimal disease activity measurement Rheumatology (Oxford). Published online May 24, doi: /rheumatology/kex183 Rheumatology (Oxford) | © The Author Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please

Download ppt "Patients were considered not in MDA (MDA<sup>−</sup>) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA<sup>+</sup>) with a score of 5, 6 or 7 points."

Similar presentations

From: An open day in the metric space

From: An open day in the metric space
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Fig. 1 Flow chart of the COBRA-light trial and its extension study

Fig. 1 Flow chart of the COBRA-light trial and its extension study
Figure 1 The spatial and temporal distribution of diarrhoea rates

Figure 1 The spatial and temporal distribution of diarrhoea rates
From: Global Banking: Recent Developments and Insights from Research*

From: Global Banking: Recent Developments and Insights from Research*
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
Test characteristics of MRI-detected inflammation for the development of arthritis in CSA patients (A) and RA in UA patients (B) during 1-year follow-up.

Test characteristics of MRI-detected inflammation for the development of arthritis in CSA patients (A) and RA in UA patients (B) during 1-year follow-up.
Error bars represent the mean (s.e.).

Error bars represent the mean (s.e.).
pSS: primary SS; Scl: scleroderma.

pSS: primary SS; Scl: scleroderma.
Figure 1. Selection of papers.

Figure 1. Selection of papers.
Fig. 1 Flow chart of study selection

Fig. 1 Flow chart of study selection
Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).

Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.
Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.
Fig 1 Perfusion index values at different time intervals in patients with successful and failed blocks. A reference line at PI 3.3 is provided. Horizontal.

Fig 1 Perfusion index values at different time intervals in patients with successful and failed blocks. A reference line at PI 3.3 is provided. Horizontal.
Fig. 1 Flow diagram of patient selection and study design.

Fig. 1 Flow diagram of patient selection and study design.
Figure 1. Percentage of trainees is represented on the y-axis for each competency/knowledge item represented in the x-axis. Only Poor/Fair (P/F) ratings.

Figure 1. Percentage of trainees is represented on the y-axis for each competency/knowledge item represented in the x-axis. Only Poor/Fair (P/F) ratings.
Figure 1. Impact ratings for prospective memory lapses for younger (~age 30), middle-age (~age 50), and older (~age 65) adults. From: Daily Memory Lapses.

Figure 1. Impact ratings for prospective memory lapses for younger (~age 30), middle-age (~age 50), and older (~age 65) adults. From: Daily Memory Lapses.
Figure 6. RRs for clinical cure rates stratified by different diseases

Figure 6. RRs for clinical cure rates stratified by different diseases
Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Similar presentations

Ads by Google